eNOS Antibody, anti-human, REAfinity™
Synonyms: NOS3, ECNOS, NOS type III, EC-NOS, NOS III
RECOMBINANT
Bioz Star90/100 Bioz rating
1 Citation
Clone:
REA451 | 33/eNOS
Type of antibody:
Primary antibodies, Recombinant antibodies
Isotype:
recombinant human IgG1
Applications:
ICFC Glossary
External link icon
Quality Assurance Certified ProductSatisfaction
guaranteed
more »
Select a conjugate:
Select a size:
Other sizes

Related products for eNOS Antibody, anti-human, REAfinity™

Intracellular flow cytometry applications
PE
Description:
Human EA.hy926 cells were fixed and permeabilized using the Cell Signaling Buffer Set A. Cells were then stained with Anti-eNOS antibodies or with the corresponding REA Control (I) antibodies (left peak) and analyzed with the MACSQuant® Analyzer. Cell debris were excluded from the analysis based on scatter signals.
Intracellular flow cytometry applications
APC
PE
Recommended dilution:
1:11
Remark:
The antibody is suited for staining of formaldehyde-fixed cells.
Data source:
Miltenyi Biotec
Conjugate:
APC
Used products:
130-106-788, 130-106-840
Description:
Human EA.hy926 cells were fixed and permeabilized using the Cell Signaling Buffer Set A. Cells were then stained with Anti-eNOS antibodies or with the corresponding REA Control (I) antibodies (left peak) and analyzed with the MACSQuant® Analyzer. Cell debris were excluded from the analysis based on scatter signals.

Application image
Recommended dilution:
1:50
Remark:
The antibody is suited for staining of formaldehyde-fixed cells.
Data source:
Miltenyi Biotec
Conjugate:
APC
Used products:
130-135-578, 130-135-508
Description:
Human EA.hy926 cells were fixed and permeabilized using the Cell Signaling Buffer Set A. Cells were then stained with Anti-eNOS antibodies or with the corresponding REA Control (I) antibodies (left peak) and analyzed with the MACSQuant® Analyzer. Cell debris were excluded from the analysis based on scatter signals.

Application image
Specifications for eNOS Antibody, anti-human, REAfinity™
Overview

Clone REA451 recognizes the human endothelial nitric oxide synthase (eNOS) antigen regardless of phosphorylation status. eNOS catalyzes the production of nitric oxide (NO) from l-arginine within the endothelium to regulate vascular tone via cGMP signaling in vascular smooth muscle, mitochondrial respiration, platelet function, inflammation, and angiogenesis. Physiologically, the most important stimulus for the continuous formation of NO is the shear stress generated by the streaming blood on the endothelial layer. Serine/threonine protein kinase Akt/PKB mediates the activation of eNOS, leading to increased NO production. Inhibition of the phosphatidylinositol-3-OH kinase/Akt pathway or mutation of the Akt site on eNOS protein attenuates the serine phosphorylation and prevents the activation of eNOS.

Additional information: Clone REA451 displays negligible binding to Fc receptors.

Alternative names

NOS3, ECNOS, NOS type III, EC-NOS, NOS III

Detailed product information

Technical specifications

Clone
REA451
Clonality
monoclonal
Isotype
recombinant human IgG1
Isotype control
REA Control Antibody (I), human IgG1
Host
human cell line
Type of antibody
Primary antibodies, Recombinant antibodies
Species reactivity
human, mouse
Cross-reactivity
mouse
Antigen
eNOS
Molecular mass of antigen [kDa]
133
Distribution of antigen
other
Entrez Gene ID
RRID
AB_2651631, AB_2651630, AB_2905192, AB_2905191

Recombinant antibodies at Miltenyi Biotec

As an innovation-powered company with a commitment to quality and excellence, Miltenyi Biotec applies cutting-edge methods to discover and develop newer and better antibodies to satisfy both market demand and regulatory requirements.

The Miltenyi way of generating best-in-class antibodies and antibody conjugates

At Miltenyi Biotec, we opt for recombinant antibodies, which enable sequence verification and optimization for lot-to-lot consistency, making them superior to hybridoma-based antibodies.

Infusing our unique expertise

Recombinants are the result of combining genetic material from different immunized animals, and using display technologies to screen in-house antibody libraries for the best antibodies. Additional analyses on existing hybridoma-based antibodies can also give rise to sequences contributing to novel recombinants.

Maximizing value for your research

By further re-engineering these antibody sequences, we can precisely control their properties to achieve the following benefits:

reduce undesirable binding to Fc gamma receptors,

  • eliminate destabilizing amino acid motifs,
  • increase specific bonding affinity for stronger, more accurate targeting, and
  • optimize fluorochrome conjugation for brighter and clearer signals.

In a final step, by synthesizing and cloning the resulting gene sequence, we achieve an expression vector that develops a cell line, which in turn produces a special recombinant antibody.

Better science with quality antibodies

Already in 2015, 100 of the world’s leading scientists collectively called for better standards and reproducibility in antibody production, proposing recombinant antibodies to circumvent variability (Baker, M. Reproducibility crisis: Blame it on the antibodies. Nature 521, 274–276 (2015). https://doi.org/10.1038/521274a). Moreover, by applying reverse engineering, which is encouraged by the EU Directive 2016/943 r, Miltenyi Biotec acts “[i]n the interest of innovation and fostering competition…” (§16).

Resources for eNOS Antibody, anti-human, REAfinity™
Certificates

To access a Certificate of Analysis (CoA) follow the link below and enter the specific lot of your product.

Get certificate

Should you wish to request additional documentation, such as a Safety Data Sheet (SDS) in other languages than English or Swedish, an SDS-replacement document, or a Certificate of Origin (CoO), please direct your inquiry to your local technical support team.

Contact technical support